Association between use of oral anti-diabetic drugs and the risk of sepsis: A nested case-control study

Chia Jen Shih, Yueh Lin Wu, Pei Wen Chao, Shu-Chen Kuo, Yu Chih Yang, Szu Yuan Li, Shuo Ming Ou, Yung Tai Chen

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Although oral antidiabetic drugs (OADs) have been associated with immunomodulation in preclinical studies, little is still known about the association between the use of OADs and the risk of sepsis. Using a cohort of patients, extracted from Taiwans National Health Insurance Research Database, with type 2 diabetes who were newly diagnosed between 2010 and 2012 and treated with OADs, we conducted a nested case-control study involving 43,015 cases (patients who were first hospitalized for sepsis) and 43,015 matched controls. Compared with non-use, metformin use was associated with a decreased risk of developing sepsis (adjusted odds ratio [OR] 0.80, 95% confidence interval [CI] 0.77-0.83, P <0.001), but meglitinide (adjusted OR 1.32, 95% CI 1.25-1.40, P <0.001) use was associated with the increased risk of developing sepsis. The risk for development of sepsis was also lower among current (adjusted OR 0.87, 95% CI 0.78-0.96) and recent (adjusted OR 0.83, 95% CI 0.73-0.94) thiazolidinedione users. Current or recent sulfonylurea use and dipeptidyl peptidase-4 inhibitor use were not significantly associated with the development of sepsis. Our results highlight the need to consider the potential pleiotropic effect of OADs against sepsis in addition to the lowering of blood glucose.
Original languageEnglish
JournalScientific Reports
Volume5
DOIs
Publication statusPublished - Oct 14 2015

Fingerprint

Case-Control Studies
Sepsis
Hypoglycemic Agents
Pharmaceutical Preparations
Odds Ratio
Confidence Intervals
Dipeptidyl-Peptidase IV Inhibitors
Immunomodulation
Metformin
National Health Programs
Type 2 Diabetes Mellitus
Blood Glucose
Databases
Research

Cite this

Association between use of oral anti-diabetic drugs and the risk of sepsis: A nested case-control study. / Shih, Chia Jen; Wu, Yueh Lin; Chao, Pei Wen; Kuo, Shu-Chen ; Yang, Yu Chih; Li, Szu Yuan; Ou, Shuo Ming; Chen, Yung Tai.

In: Scientific Reports, Vol. 5, 14.10.2015.

Research output: Contribution to journalArticle

Shih, Chia Jen ; Wu, Yueh Lin ; Chao, Pei Wen ; Kuo, Shu-Chen ; Yang, Yu Chih ; Li, Szu Yuan ; Ou, Shuo Ming ; Chen, Yung Tai. / Association between use of oral anti-diabetic drugs and the risk of sepsis: A nested case-control study. In: Scientific Reports. 2015 ; Vol. 5.
@article{2d3fe85c13094599965141abb08fe190,
title = "Association between use of oral anti-diabetic drugs and the risk of sepsis: A nested case-control study",
abstract = "Although oral antidiabetic drugs (OADs) have been associated with immunomodulation in preclinical studies, little is still known about the association between the use of OADs and the risk of sepsis. Using a cohort of patients, extracted from Taiwans National Health Insurance Research Database, with type 2 diabetes who were newly diagnosed between 2010 and 2012 and treated with OADs, we conducted a nested case-control study involving 43,015 cases (patients who were first hospitalized for sepsis) and 43,015 matched controls. Compared with non-use, metformin use was associated with a decreased risk of developing sepsis (adjusted odds ratio [OR] 0.80, 95{\%} confidence interval [CI] 0.77-0.83, P <0.001), but meglitinide (adjusted OR 1.32, 95{\%} CI 1.25-1.40, P <0.001) use was associated with the increased risk of developing sepsis. The risk for development of sepsis was also lower among current (adjusted OR 0.87, 95{\%} CI 0.78-0.96) and recent (adjusted OR 0.83, 95{\%} CI 0.73-0.94) thiazolidinedione users. Current or recent sulfonylurea use and dipeptidyl peptidase-4 inhibitor use were not significantly associated with the development of sepsis. Our results highlight the need to consider the potential pleiotropic effect of OADs against sepsis in addition to the lowering of blood glucose.",
author = "Shih, {Chia Jen} and Wu, {Yueh Lin} and Chao, {Pei Wen} and Shu-Chen Kuo and Yang, {Yu Chih} and Li, {Szu Yuan} and Ou, {Shuo Ming} and Chen, {Yung Tai}",
year = "2015",
month = "10",
day = "14",
doi = "10.1038/srep15260",
language = "English",
volume = "5",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Association between use of oral anti-diabetic drugs and the risk of sepsis: A nested case-control study

AU - Shih, Chia Jen

AU - Wu, Yueh Lin

AU - Chao, Pei Wen

AU - Kuo, Shu-Chen

AU - Yang, Yu Chih

AU - Li, Szu Yuan

AU - Ou, Shuo Ming

AU - Chen, Yung Tai

PY - 2015/10/14

Y1 - 2015/10/14

N2 - Although oral antidiabetic drugs (OADs) have been associated with immunomodulation in preclinical studies, little is still known about the association between the use of OADs and the risk of sepsis. Using a cohort of patients, extracted from Taiwans National Health Insurance Research Database, with type 2 diabetes who were newly diagnosed between 2010 and 2012 and treated with OADs, we conducted a nested case-control study involving 43,015 cases (patients who were first hospitalized for sepsis) and 43,015 matched controls. Compared with non-use, metformin use was associated with a decreased risk of developing sepsis (adjusted odds ratio [OR] 0.80, 95% confidence interval [CI] 0.77-0.83, P <0.001), but meglitinide (adjusted OR 1.32, 95% CI 1.25-1.40, P <0.001) use was associated with the increased risk of developing sepsis. The risk for development of sepsis was also lower among current (adjusted OR 0.87, 95% CI 0.78-0.96) and recent (adjusted OR 0.83, 95% CI 0.73-0.94) thiazolidinedione users. Current or recent sulfonylurea use and dipeptidyl peptidase-4 inhibitor use were not significantly associated with the development of sepsis. Our results highlight the need to consider the potential pleiotropic effect of OADs against sepsis in addition to the lowering of blood glucose.

AB - Although oral antidiabetic drugs (OADs) have been associated with immunomodulation in preclinical studies, little is still known about the association between the use of OADs and the risk of sepsis. Using a cohort of patients, extracted from Taiwans National Health Insurance Research Database, with type 2 diabetes who were newly diagnosed between 2010 and 2012 and treated with OADs, we conducted a nested case-control study involving 43,015 cases (patients who were first hospitalized for sepsis) and 43,015 matched controls. Compared with non-use, metformin use was associated with a decreased risk of developing sepsis (adjusted odds ratio [OR] 0.80, 95% confidence interval [CI] 0.77-0.83, P <0.001), but meglitinide (adjusted OR 1.32, 95% CI 1.25-1.40, P <0.001) use was associated with the increased risk of developing sepsis. The risk for development of sepsis was also lower among current (adjusted OR 0.87, 95% CI 0.78-0.96) and recent (adjusted OR 0.83, 95% CI 0.73-0.94) thiazolidinedione users. Current or recent sulfonylurea use and dipeptidyl peptidase-4 inhibitor use were not significantly associated with the development of sepsis. Our results highlight the need to consider the potential pleiotropic effect of OADs against sepsis in addition to the lowering of blood glucose.

UR - http://www.scopus.com/inward/record.url?scp=84944398239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944398239&partnerID=8YFLogxK

U2 - 10.1038/srep15260

DO - 10.1038/srep15260

M3 - Article

AN - SCOPUS:84944398239

VL - 5

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

ER -